GRDX · GridAI Technologies Corp. · Insider Trading

On December 19, 2025, the Reporting Person was granted 1,000,000 restricted stock units. 250,000 restricted stock units vested on March 31, 2026 and an additional 250,000 restricted stock units vested on June 30, 2026 in each case, based on satisfaction of performance objectives.

On December 19, 2025, the Reporting Person was granted 1,000,000 restricted stock units. 250,000 restricted stock units vested on March 31, 2026 and an additional 250,000 restricted stock units vested on June 30, 2026 in each case, based on satisfaction of performance objectives.

On January 1, 2026, the Reporting Person was granted 40,000 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vested immediately upon issuance on January 1, 2026.

On January 1, 2026, the Reporting Person was granted 40,000 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vested immediately upon issuance on January 1, 2026.

On January 1, 2026, the Reporting Person was granted 40,000 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vested immediately upon issuance on January 1, 2026.

On January 1, 2026, the Reporting Person was granted 40,000 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vested immediately upon issuance on January 1, 2026.

On December 22, 2025, the Reporting Person was granted 65,000 restricted stock units, to be settled in shares of common stock, par value $0.0001. The restricted stock units vested immediately upon issuance on December 22, 2025.

On December 22, 2025, the Reporting Person was granted 40,000 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vested immediately upon issuance on December 22, 2025.

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Includes unvested RSUs.

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Includes unvested RSUs.

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $1.05 - $1.16, inclusive. The Reporting Person undertakes to provide Entero Therapeutics, Inc. ("Entero"), any security holder of Entero, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Includes unvested RSUs.

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $1.05 - $1.16, inclusive. The Reporting Person undertakes to provide Entero Therapeutics, Inc. ("Entero"), any security holder of Entero, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Includes unvested RSUs.

On June 11, 2024, the Reporting Person was granted 24,889 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest in three equal increments on July 1, 2024, September 30, 2024, and December 31, 2024.

Includes unvested RSUs.

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Includes unvested RSUs.

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Includes unvested RSUs.

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.90 - $5.175, inclusive. The Reporting Person undertakes to provide First Wave BioPharma, Inc. ("First Wave"), any security holder of First Wave, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Includes unvested RSUs.

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.90 - $5.175, inclusive. The Reporting Person undertakes to provide First Wave BioPharma, Inc. ("First Wave"), any security holder of First Wave, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Includes unvested RSUs.

On March 13, 2024, the Issuer acquired ImmunogenX, Inc. ("ImmunogenX") in accordance with the terms of the Agreement and Plan of Merger, dated March 13, 2024, by and among the Issuer, IMMUNO Merger Sub I, Inc., IMMUNO Merger Sub II, LLC, and ImmunogenX (the "Merger"). The shares of common stock, par value $0.0001 per share (the "Common Stock"), of the Issuer and the shares of Series G Preferred Stock, par value $0.0001 per share (the "Preferred Stock") of the Issuer were received by the Reporting Person in the Merger in exchange for an aggregate of 352,000 shares of common stock, par value $0.0001, of ImmunogenX and 1,375,427 shares of preferred stock, par value $0.0001 per share, of ImmunogenX.

Held directly by the Jack A. Syage and Elizabeth T. Syage Revocable Trust Dated November 30, 1999, in which the Reporting Person and his spouse serve as the Trustees. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Held directly by the Jack A. Syage and Elizabeth T. Syage Revocable Trust Dated November 30, 1999, in which the Reporting Person and his spouse serve as the Trustees. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

On March 13, 2024, the Issuer acquired ImmunogenX, Inc. ("ImmunogenX") in accordance with the terms of the Agreement and Plan of Merger, dated March 13, 2024, by and among the Issuer, IMMUNO Merger Sub I, Inc., IMMUNO Merger Sub II, LLC, and ImmunogenX (the "Merger"). The shares of common stock, par value $0.0001 per share (the "Common Stock"), of the Issuer and the shares of Series G Preferred Stock, par value $0.0001 per share (the "Preferred Stock") of the Issuer were received by the Reporting Person in the Merger in exchange for an aggregate of 352,000 shares of common stock, par value $0.0001, of ImmunogenX and 1,375,427 shares of preferred stock, par value $0.0001 per share, of ImmunogenX.

The shares of Preferred Stock will automatically convert into shares of Common Stock at a ratio of 1-for-1,000 on the third business day after the date that the Issuer's stockholders approve the conversion of the Preferred Stock into shares of Common Stock, subject to certain beneficial ownership limitations. The Preferred Stock contains a conversion limitation prohibiting the Reporting Person from converting the Preferred Stock until such time as the Reporting Person would not beneficially own after such conversion more than 19.9% of the then issued and outstanding Common Stock. Due to this blocker, the Preferred Stock would not fully convertible at this time upon stockholder approval. The blocker percentage may be decreased to 4.9% or otherwise adjusted by the Reporting Person upon 61 days' notice to the Issuer.

The Preferred Stock is perpetual and therefore has no expiration date.

On March 13, 2024, the Issuer acquired ImmunogenX, Inc. ("ImmunogenX") in accordance with the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated March 13, 2024, by and among the Issuer, IMMUNO Merger Sub I, Inc., IMMUNO Merger Sub II, LLC, and ImmunogenX (the "Merger"). The shares of common stock, par value $0.0001 per share (the "Common Stock"), of the Issuer and the shares of Series G Preferred Stock, par value $0.0001 per share (the "Preferred Stock") of the Issuer were received by the Reporting Person in the Merger in exchange for an aggregate of 34,159 shares of preferred stock, par value $0.0001 per share, of ImmunogenX.

Held directly by the Chaitan Khosla Living Trust, in which the Reporting Person serves as the sole Trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

The shares of Preferred Stock will automatically convert into shares of Common Stock at a ratio of 1-for-1,000 on the third business day after the date that the Issuer's stockholders approve the conversion of the Preferred Stock into shares of Common Stock, subject to certain beneficial ownership limitations. The Preferred Stock contains a conversion limitation prohibiting the Reporting Person from converting the Preferred Stock until such time as the Reporting Person would not beneficially own after such conversion more than 19.9% of the then issued and outstanding Common Stock. The blocker percentage may be decreased to 4.9% or otherwise adjusted by the Reporting Person upon 61 days' notice to the Issuer.

On March 13, 2024, the Issuer acquired ImmunogenX, Inc. ("ImmunogenX") in accordance with the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated March 13, 2024, by and among the Issuer, IMMUNO Merger Sub I, Inc., IMMUNO Merger Sub II, LLC, and ImmunogenX (the "Merger"). The shares of common stock, par value $0.0001 per share (the "Common Stock"), of the Issuer and the shares of Series G Preferred Stock, par value $0.0001 per share (the "Preferred Stock") of the Issuer were received by the Reporting Person in the Merger in exchange for an aggregate of 34,159 shares of preferred stock, par value $0.0001 per share, of ImmunogenX.

The Preferred Stock is perpetual and therefore has no expiration date.

Held directly by the Chaitan Khosla Living Trust, in which the Reporting Person serves as the sole Trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Pursuant to the terms of the Merger Agreement, the option to acquire 20,000 shares of common stock, par value $0.0001 per share, of ImmunogenX (the "Original Amount") at an exercise price of $2.14 per share (the "Original Exercise Price") that was originally granted on February 1, 2021 under the ImmunogenX 2021 Stock Option Plan was assumed by the Issuer and converted into an option to purchase a number of shares of Common Stock of the Issuer equal to the Original Amount multiplied by 2.649 (the "Exchange Ratio") at an exercise price equal to the Original Exercise Price divided by the Exchange Ratio. The option will continue to be governed by the same terms and conditions as were applicable to such option immediately prior to the Effective Time.

The option was fully vested at the effective time of the Merger (the "Effective Time").

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Includes unvested RSUs.

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Includes unvested RSUs.

On January 2, 2024, the Reporting Person was granted 7,000 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning April 1, 2024.

Includes unvested RSUs.

On January 2, 2024, the Reporting Person was granted 19,633 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning April 1, 2024.

Includes unvested RSUs.

On January 2, 2024, the Reporting Person was granted 19,633 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning April 1, 2024.

Includes unvested RSUs.

On January 2, 2024, the Reporting Person was granted 19,633 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning April 1, 2024.

Includes unvested RSUs.

On January 2, 2024, the Reporting Person was granted 19,633 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning April 1, 2024.

Includes unvested RSUs.

On January 2, 2024, the Reporting Person was granted 20,000 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning April 1, 2024.

Includes unvested RSUs.

On December 29, 2023, the Reporting Person was granted 12,614 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest upon closing of the Issuer's proposed acquisition of ImmunogenX, Inc.

Includes unvested RSUs.

On December 29, 2023, the Reporting Person was granted 17,660 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest upon closing of the Issuer's proposed acquisition of ImmunogenX, Inc.

Includes unvested RSUs.

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.291 to $0.293. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Includes unvested RSUs.

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.291 to $0.293. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Includes unvested RSUs.

Includes unvested RSUs.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3001 to $0.3013. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Includes unvested RSUs.

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.49 to $1.61. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Includes unvested RSUs.

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.49 to $1.61. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Includes unvested RSUs.

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.41 to $2.60. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Includes unvested RSUs.

All amounts reflect the 1:7 reverse stock split effective as of January 18, 2023

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.41 to $2.60. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Includes unvested RSUs.

All amounts reflect the 1:7 reverse stock split effective as of January 18, 2023.

On January 3, 2023, the Reporting Person was granted 84,745 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning March 31, 2023.

Includes unvested RSUs.

On January 3, 2023, the Reporting Person was granted 150,000 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning March 31, 2023.

Includes unvested RSUs.

On January 3, 2023, the Reporting Person was granted 84,745 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning March 31, 2023.

Includes unvested RSUs.

On January 3, 2023, the Reporting Person was granted 84,745 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning March 31, 2023.

Includes unvested RSUs.

On January 3, 2023, the Reporting Person was granted 300,000 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning March 31, 2023.

Includes unvested RSUs.

On January 3, 2023, the Reporting Person was granted 84,745 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning March 31, 2023.

Includes unvested RSUs.

On January 3, 2023, the Reporting Person was granted 84,745 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning March 31, 2023.

Includes unvested RSUs.

The stock option vests in three equal annual installments commencing on March 1, 2023.

The stock option vests in 36 equal monthly installments over a term of three (3) years beginning on the date of grant, conditioned on Mr. Sapirstein's continued employment by First Wave BioPharma, Inc. on the applicable vesting date.

The stock option vests in equal quarterly installments on each of March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022.